Kronos Historical Financial Ratios
| KRON Stock | USD 0.95 0.01 1.04% |
Kronos Bio is lately reporting on over 91 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Kronos Bio financial condition quickly.
Kronos |
About Kronos Financial Ratios Analysis
Kronos BioFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Kronos Bio investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Kronos financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Kronos Bio history.
Kronos Bio Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Kronos Bio stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Kronos Bio sales, a figure that is much harder to manipulate than other Kronos Bio multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Asset Turnover
The ratio of net sales to average total assets, indicating how efficiently a company uses its assets to generate sales.Most ratios from Kronos Bio's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Kronos Bio current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.At this time, Kronos Bio's Income Quality is very stable compared to the past year. As of the 30th of November 2024, Tangible Book Value Per Share is likely to grow to 2.84, though Free Cash Flow Yield is likely to grow to (1.04).
| 2021 | 2022 | 2023 | 2024 (projected) | Current Ratio | 25.51 | 11.37 | 7.24 | 6.88 | Net Debt To EBITDA | 2.08 | 0.35 | 0.3 | 0.28 |
Kronos Bio fundamentals Correlations
Click cells to compare fundamentals
Kronos Bio Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kronos Bio fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | (61.88) | 3.47 | 2.16 | 0.37 | 0.45 | 0.48 | |
| Book Value Per Share | (0.44) | 8.61 | 6.3 | 4.35 | 2.75 | 2.84 | |
| Free Cash Flow Yield | (0.0126) | (0.0294) | (0.16) | (1.01) | (1.1) | (1.04) | |
| Operating Cash Flow Per Share | (0.28) | (0.7) | (2.15) | (1.62) | (1.36) | (1.43) | |
| Capex To Depreciation | 8.28 | 11.4 | 2.15 | 0.25 | 0.32 | 0.3 | |
| Pb Ratio | (61.88) | 3.47 | 2.16 | 0.37 | 0.45 | 0.48 | |
| Free Cash Flow Per Share | (0.34) | (0.88) | (2.23) | (1.63) | (1.37) | (1.44) | |
| Roic | 0.69 | (0.0903) | (0.43) | (0.54) | (0.75) | (0.71) | |
| Net Income Per Share | (0.29) | (1.19) | (2.72) | (2.3) | (1.95) | (2.05) | |
| Payables Turnover | 0.4 | 1.07 | 4.09 | 0.88 | 0.8 | 1.06 | |
| Cash Per Share | 1.74 | 11.6 | 8.78 | 4.24 | 3.0 | 3.96 | |
| Pocfratio | (95.21) | (42.6) | (6.31) | (1.0) | (0.92) | (0.96) | |
| Capex To Operating Cash Flow | (0.2) | (0.25) | (0.0361) | (0.006346) | (0.008641) | (0.009073) | |
| Pfcf Ratio | (79.64) | (34.02) | (6.09) | (1.0) | (0.91) | (0.96) | |
| Days Payables Outstanding | 908.58 | 341.3 | 89.26 | 412.76 | 474.68 | 775.38 | |
| Income Quality | 0.94 | 0.43 | 0.78 | 0.68 | 0.7 | 0.83 | |
| Roe | 0.66 | (0.14) | (0.43) | (0.53) | (0.71) | (0.67) | |
| Ev To Operating Cash Flow | (93.08) | (31.26) | (3.72) | (0.51) | (0.46) | (0.48) | |
| Pe Ratio | (93.13) | (25.2) | (4.99) | (0.7) | (0.64) | (0.67) | |
| Ev To Free Cash Flow | (77.86) | (24.96) | (3.59) | (0.5) | (0.46) | (0.48) | |
| Earnings Yield | (0.0107) | (0.0397) | (0.2) | (1.42) | (1.56) | (1.48) | |
| Net Debt To E B I T D A | 2.07 | 5.4 | 2.08 | 0.35 | 0.3 | 0.28 | |
| Current Ratio | 34.6 | 32.65 | 25.51 | 11.37 | 7.24 | 6.88 | |
| Tangible Book Value Per Share | (0.44) | 8.61 | 6.3 | 4.35 | 2.75 | 2.84 | |
| Graham Number | 1.69 | 15.15 | 19.65 | 15.01 | 11.0 | 8.49 | |
| Shareholders Equity Per Share | (0.44) | 8.61 | 6.3 | 4.35 | 2.75 | 2.84 | |
| Capex Per Share | 0.0556 | 0.18 | 0.0778 | 0.0103 | 0.0118 | 0.0112 | |
| Graham Net Net | (0.64) | 10.29 | 7.94 | 3.26 | 2.06 | 3.01 | |
| Enterprise Value Over E B I T D A | (90.5) | (14.87) | (2.98) | (0.36) | (0.3) | (0.31) | |
| Price Earnings Ratio | (93.13) | (25.2) | (4.99) | (0.7) | (0.64) | (0.67) | |
| Price Book Value Ratio | (61.88) | 3.47 | 2.16 | 0.37 | 0.45 | 0.48 | |
| Days Of Payables Outstanding | 908.58 | 341.3 | 89.26 | 412.76 | 474.68 | 775.38 | |
| Price To Operating Cash Flows Ratio | (95.21) | (42.6) | (6.31) | (1.0) | (0.92) | (0.96) | |
| Price To Free Cash Flows Ratio | (79.64) | (34.02) | (6.09) | (1.0) | (0.91) | (0.96) | |
| Ebt Per Ebit | 0.96 | 1.52 | 1.0 | 0.97 | 0.92 | 1.17 |
Pair Trading with Kronos Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kronos Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kronos Bio will appreciate offsetting losses from the drop in the long position's value.Moving against Kronos Stock
| 0.69 | VTRS | Viatris | PairCorr |
| 0.63 | BMY | Bristol Myers Squibb Sell-off Trend | PairCorr |
| 0.63 | GILD | Gilead Sciences | PairCorr |
| 0.6 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.42 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Kronos Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kronos Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kronos Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kronos Bio to buy it.
The correlation of Kronos Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kronos Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kronos Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kronos Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kronos Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.